pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
392
stories
2h
STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
stat
10h
nChroma halves workforce, BioXcel lets execs go
biospace
21h
9 biotechs will cut at least half their California workforces
biospace
1d
Recon: FDA approves drugs for four rare diseases; Pfizer signs $2.6B licensing deal in China for in vivo CAR-T
raps
1d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
1d
Government actions are hitting smaller biotechs the hardest: Report
biospace
1d
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
biopharma dive
1d
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
biospace
1d
In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
biospace
1d
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
1d
Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics
endpoints
1d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
1d
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
1d
Less than a year into the job, Everett Cunningham steps down as Quanterix CEO
fiercebiotech
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
2d
STAT+: ‘Medicare for More’ gains traction
stat
3d
STAT+: Suing Joe the Plumber and Microsoft, and diminishing raises
stat
3d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
3d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
3d
Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
fiercebiotech
3d
BeOne, Hengrui top list of China’s most powerful drugmakers
stat
3d
BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
biospace
3d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
4d
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
stat
4d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
6d
STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
stat
6d
STAT+: HHS plans funding for research into ibogaine for PTSD
stat
6d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
6d
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
stat
6d
Across the U.S., homegrown experiments aim to save kids from their phones
stat
← prev
page 1 of 14
next →